Autotaxin

Autotaxin Related Products (35):

By Type:	Pan (4) Selective (17)
By Effects:	Inhibitors (32) Modulators (2)

Cat. No.	Product Name	Effect	Purity

HY-101772

Ziritaxestat	Inhibitor	99.93%
Ziritaxestat (GLPG1690) is a first-in-class autotaxin (ATX) inhibitor, with an IC₅₀ of 131 nM and a K_i of 15 nM.

HY-13344

PF-8380	Inhibitor	99.05%
PF-8380 is a potent autotaxin inhibitor with an IC₅₀ of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.

HY-19329

HA130	Inhibitor	98.79%
HA130 is a selective autotaxin (ATX) inhibitor with an IC₅₀ of 28 nM.

HY-145344

ONO-8430506	Inhibitor	99.90%
ONO-8430506 is an orally bioavailable and potent autotaxin (ATX)/ENPP2 inhibitor with the IC₉₀ of 100 nM for ATX activity in mouse plasma.

HY-124772

BI-2545	Inhibitor	98.85%
BI-2545, a chemical probe, is a potent autotaxin (ATX) inhibitor that significantly reduces LPA, with IC₅₀s of 2.2 nM and 3.4 nM for human ATX and rat ATX, respectively.

HY-181931

Autotaxin-IN-8	Inhibitor
Autotaxin-IN-8 (Compound 14E) is an orally active Autotaxin inhibitor with an IC₅₀ of 14.2 nM against hAutotaxin. Autotaxin-IN-8 inhibits Autotaxin activity, MAPK activation, LPAR1 and p-ERK1/2. Autotaxin-IN-8 reduces the phosphorylation levels of JNK and p38. Autotaxin-IN-8 decreases collagen deposition in a mouse model of pulmonary fibrosis. Autotaxin-IN-8 can be used in research related to pulmonary fibrosis.

HY-179580

EL244	Inhibitor	99.55%
EL244 is a dua Autotaxin (ATX) (IC₅₀ = 50 nM) inhibitor and PPARγ (IC₅₀ = 1.3 μM; K_d = 1.3 μM) agonist. EL244 demonstrates low cytotoxicity in human HepG2 cells (EC₅₀ = 81.2 μM) with minimal inhibition of the cardiac hERG potassium channel (12% at 25 μM). EL244 significantly reduces pulmonary Lysophosphatidic Acid (LPA) levels, attenuates fibrosis, and restores respiratory function with limited systemic absorption in vivo. EL244 can be used for idiopathic pulmonary fibrosis and interstitial lung disease (ILD) research.

HY-119601

GRI918013	Inhibitor
GRI918013 (compound 1) is a selective and competitive autotaxin (ATX/NPP2) inhibitor with anti-invasive and anti-metastatic activity. GRI918013 competitively binds to ATX, blocking lipid substrates such as lysophosphatidylcholine (LPC) from entering the ATX active site, thereby inhibiting ATX-mediated hydrolysis of LPC to lysophosphatidic acid (LPA), and consequently inhibiting ATX-LPA axis-related tumor cell invasion and metastasis. GRI918013 inhibits ATX-mediated hydrolysis of the LPL substrate FS-3 (IC₅₀=31.42 nM, K_i=12.98 nM). GRI918013 can be used in research on cancer invasion and metastasis, such as melanoma, and can also serve as a tool compound for ATX-LPA axis-related diseases such as fibrotic diseases, neuropathic pain, and cholestatic pruritus.

HY-13344A

PF-8380 hydrochloride	Inhibitor	99.14%
PF-8380 hydrochloride is a potent autotaxin inhibitor with an IC₅₀ of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.

HY-135053

Autotaxin-IN-3	Inhibitor	98.05%
Autotaxin-IN-3 is a Autotaxin(ATX) inhibitor with an IC₅₀ of 2.4 nM, compound 33, sourced from patent WO2018212534A1.

HY-107781

PAT-505	Inhibitor	99.47%
PAT-505 is a potent, selective, noncompetitive and orally available autotaxin inhibitor, with an IC₅₀ of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma.

HY-145561

Cudetaxestat	Inhibitor	98.32%
Cudetaxestat (BLD-0409; PAT-409) is an orally active and noncompetitive autotaxin (ATX) inhibitor. Cudetaxestat inhibits the activity of ATX, reduces the production of LPA, and thereby blocks the signal transduction of the ATX-LPA axis. Cudetaxestat can still maintain nanomolar-level biochemical efficacy even when the concentration of the LPC substrate increases. Cudetaxestat can be used for the study of various diseases related to LPA including fibrosis, tumor metastasis, inflammation and autoimmune diseases, etc.

HY-12812

Autotaxin modulator 1	Modulator	99.40%
Autotaxin modulator 1 is an autotaxin (ATX) enzyme inhibitor, extracted from patent WO 2014018881 A1, Compound Example 12b. Autotaxin modulator 1 is expected to be useful for researching demyelination due to injury or disease, as well as for researching proliferative disorders such as cancer.

HY-103267

S32826 disodium	Inhibitor	98.85%
S32826 disodium is a potent autotaxin inhibitor, with an IC₅₀ of 8.8 nM. S32826 disodium shows similar inhibitory effects at various autotaxin isoforms (α, β and γ). S32826 disodium inhibits LPA release from adipocytes.

HY-133019

ATX inhibitor 5	Inhibitor	99.20%
ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC₅₀ of 15.3 nM. ATX inhibitor 5 shows anti-hepatofibrosis effects and reduces CCl4-induced hepatic fibrosis level prominently.

HY-103035

BIO-32546	Modulator	99.05%
BIO-32546 (example 12b, S-isomer) is an autotaxin (ATX) modulator (IC₅₀: 1 nM), extracted from the patent US20170158687A1.

HY-150614

Autotaxin-IN-6	Inhibitor	99.88%
Autotaxin-IN-6 (compound 23) is a potent autotaxin (ATX) inhibitor with an IC₅₀ value of 30 nM. Autotaxin-IN-6 can reduce cell migration. Autotaxin-IN-6 can be used for researching anticancer.

HY-143237

ATX inhibitor 11	Inhibitor	99.44%
ATX inhibitor 11 (compound 13c) is a potent ATX (autotaxin) inhibitor, with an IC₅₀ of 2.7 nM. ATX inhibitor 11 can typically alleviate the severity of fibrosis tissues and effectively reduce the deposition of fibrotic biomarker α-SMA in mice fibrosis model. ATX inhibitor 11 can be used for lung fibrosis research.

HY-135088

Autotaxin-IN-4	Inhibitor
Autotaxin-IN-4 (compound 51), extracted from patent WO2018212534A1, is an Autotaxin inhibitor. Autotaxin-IN-4 has the potential to treat idiopathic pulmonary fibrosis.

HY-103267A

S32826	Inhibitor
S32826 is a potent autotaxin inhibitor, with an IC₅₀ of 8.8 nM. S32826 shows similar inhibitory effects at various autotaxin isoforms (α, β and γ). S32826 inhibits LPA release from adipocytes.

Name
Email *

	Sorry, but the email address you supplied was invalid.